Dr. Schneider is a medical oncologist, Professor of Medicine and Medical/Molecular Genetics at the Indiana University Melvin and Bren Simon Cancer Center, and the Vera Bradley Chair of Oncology. Dr. Schneider is also co-leader of the Indiana University Grand Challenge Precision Health Initiative, which is working together, through team science, to discover targeted treatments, cures and preventions where there currently are none. Through his research, he has identified several biomarkers or characteristics that predict which patients might suffer severe side effects from chemotherapy before they ever receive it. He has led several clinical studies and published over 70 original research articles in high impact medical journals and has three provisional patents for biomarkers. He is an ad hoc reviewer for multiple medical journals. His clinical and laboratory accomplishments have resulted in a multitude of invitations to advisory boards, expert panels, invited presentations, and awards; with some of those highlights as follows: named to the Susan G. Komen Scientific Advisory Council; an international advisory board comprised of 50 of the most accomplished breast cancer oncologists, surgeons, and scientists across the world. His work was highlighted in the “Best of the American Society of Clinical Oncology” program as one of the most important cancer breakthroughs in 2011. In 2012, he was named to the “forty under 40” by the Indianapolis business journal; a designation as one of the most influential people in the Indianapolis metro area under age 40. In 2012, he also received the Susan G. Komen for the Cure Lifetime Achievement Award. In 2014, Dr. Schneider founded and became the Director of the Indiana University Health Precision Genomics Program. This program uses cutting-edge next generation genomic sequencing of cancer patients’ tumors to uncover novel therapies for those without standard options. To date over 3000 patients across the U.S. have had their tumors sequenced in this program. This program was a Finalist for “Advancements in Health Care” by the Indianapolis Business Journal in 2016. Based on his clinical advances and implementation in Precision Medicine, he is now a system-wide Vice President at IU Health.